Back to results
US 2021/0171505 A1Published application
Substituted pyrazole-pyrimidines, variants thereof, and uses therefore
AssigneeAfferent Pharmaceuticals, Inc.
InventorsRonald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
Life of this patent
Estimating the term…
Abstract
Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula I and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors: In one embodiment, the P2X3 and/or P2X2/3 antagonists disclosed herein are potentially useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
Claims18
A compound of Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- ring
- is selected from the group consisting of:
- W is CH2, NH, N—C1-6alkylene, O or S;
- X6 is N;
- Y is hydrogen or —NHRd;
- wherein Rd is selected from the group consisting of hydrogen, C1-12alkyl, C3-12cycloalkyl, aryl, and heteroaryl;
- wherein each of the C1-12alkyl, C3-12cycloalkyl, aryl, and heteroaryl is optionally substituted with one to three substituents independently selected from halogen, hydroxyl and C1-6alkyl;
- D is an optional oxygen;
- each occurrence of R1 is independently selected from the group consisting of hydrogen, hydroxyl, C1-6alkyl, C2-6alkenyl, and C2-6alkynyl;
- wherein each of the C1-6alkyl, C2-6alkenyl, and C2-6alkynyl is optionally substituted with one to three substituents independently selected from halogen and hydroxyl;
- each occurrence of R2 is independently selected from the group consisting of hydrogen, halogen, —NH—Rf, —C(O)—NHRf, —C(O)—C1-12alkyl, C2-12alkenyl, C2-12alkynyl, and —O—C1-12alkyl;
- each occurrence of Rf is independently selected from the group consisting of hydrogen, C1-12alkyl, hydroxyl, —SO2—NH2, and —SO2—C1-6alkyl;
- and
- R7 is selected from the group consisting of hydrogen, C1-12alkyl, and C3-12cycloalkyl.
12 more elements
(canceled)
7-8. (canceled)
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof,
- wherein:
- R is selected from the group consisting of hydrogen, hydroxyl, C1-6alkyl, C2-6alkenyl, and C2-6alkynyl;
- wherein each of the C1-6alkyl, C2-6alkenyl, and C2-6alkynyl is optionally substituted with one to three substituents independently selected from halogen and hydroxyl.
1 more element
(canceled)
(canceled)
19-20. (canceled)
Dependencies are inferred from the claim text.